Patents by Inventor Matthew Alexander Sleeman
Matthew Alexander Sleeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124596Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: October 31, 2023Publication date: April 18, 2024Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 11897949Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: GrantFiled: May 28, 2021Date of Patent: February 13, 2024Assignee: MedImmune LimitedInventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Publication number: 20210347871Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: ApplicationFiled: May 28, 2021Publication date: November 11, 2021Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Patent number: 11053307Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: GrantFiled: September 17, 2019Date of Patent: July 6, 2021Assignee: MedImmune LimitedInventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Publication number: 20210147559Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: October 14, 2020Publication date: May 20, 2021Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20200123241Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: ApplicationFiled: September 17, 2019Publication date: April 23, 2020Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Patent number: 10457728Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: GrantFiled: December 21, 2017Date of Patent: October 29, 2019Assignee: MedImmune LimitedInventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Publication number: 20190309077Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: January 8, 2019Publication date: October 10, 2019Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20190040145Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: May 15, 2018Publication date: February 7, 2019Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20180222971Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: ApplicationFiled: December 21, 2017Publication date: August 9, 2018Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Patent number: 9884911Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: GrantFiled: February 2, 2015Date of Patent: February 6, 2018Assignee: MEDIMMUNE LIMITEDInventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Patent number: 9701746Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.Type: GrantFiled: April 18, 2016Date of Patent: July 11, 2017Assignee: MedImmune LimitedInventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
-
Publication number: 20160297878Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.Type: ApplicationFiled: April 18, 2016Publication date: October 13, 2016Applicant: MedImmune LimitedInventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
-
Patent number: 9315571Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.Type: GrantFiled: January 24, 2006Date of Patent: April 19, 2016Assignees: Elan Pharma International Limited, MedImmune LimitedInventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
-
Publication number: 20150376285Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: June 29, 2015Publication date: December 31, 2015Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20150274818Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: ApplicationFiled: February 2, 2015Publication date: October 1, 2015Inventors: DARREN SCHOFIELD, MATTHEW ALEXANDER SLEEMAN, IAIN PATRICK CHESSELL, JONATHAN HATCHER, DAVID LOWE
-
Patent number: 9085628Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: GrantFiled: July 12, 2013Date of Patent: July 21, 2015Assignees: MedImmune Limited, Zenyth Operations Pty. Ltd.Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Publication number: 20140079708Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: ApplicationFiled: July 12, 2013Publication date: March 20, 2014Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 8506960Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: GrantFiled: March 27, 2007Date of Patent: August 13, 2013Assignees: MedImmune Limited, Zenyth Operations Pty. Ltd.Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 8263075Abstract: Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.Type: GrantFiled: March 27, 2007Date of Patent: September 11, 2012Assignee: MedImmune LimitedInventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri